The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
Blockade of IL-23: What is in the Pipeline?
Open accessAbstract
Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn’s disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This mechanistic framework explains the efficacy of biologic therapies targeting TNF, IL-17, and IL-23, which interrupt key nodes in the pathogenic network.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [22]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psoriasis is a complex disease with multiple molecules and cells involved that develops through a tightly linked sequence of innate and adaptive immune events in genetically predisposed skin, with the IL-23/Th17 axis acting as the central pathway.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although earlier models emphasized a Th1-mediated process, current understanding places IL-23-driven pathogenic Th17 responses at the core of the disease.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As this inflammatory process persists, the lesions become self-sustaining: IL-23 maintains pathogenic lymphocytes, IL-17 and IL-22 reshape the epidermis, TNF-α amplifies the inflammatory network, and angiogenic factors such as VEGF remodel the microvasculature.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These populations produce IL-17A, IL-17F, IL-22, TNF-α, and other mediators that act directly on keratinocytes.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [22]
Experimental — accuracy not yet measured
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., & Trinchieri, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.827 · Cited by 1,953
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
Self-citationIncreased expression of interleukin 17 in inflammatory bowel disease
Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., & Fujiyama, Y. (2003) · Gut · doi:10.1136/gut.52.1.65 · Cited by 1,713
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Research works printed but not linked: 5
- Hong, 2021, Real, Crohns Colitis 360, 3
- D’Haens, 2021, Risankizumab induction therapy in patients with moderate-to-severe Crohn’s disease with intolerance or inadequate response to conventional and/or biologic therapy: results from the phase 3 advance study, E28
- Bossuyt, 2021, Risankizumab therapy induces improvements in endoscopic endpoints in patients with moderate-to-severe Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE studies, S033
- Schreiber, 2021, Risankizumab induces early clinical remission and response in patients with moderate-to-severe Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE studies, S026
- Lichtenstein, 2020, Impact of Mirikizumab treatment on health-related quality of life in patients with ulcerative colitis: a phase 2 study analysis using the SF-36 V2 Standard, Gastroenterology, 158, S-S-1205
Cited by
Le Berre, C., Honap, S., & Peyrin-Biroulet, L. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00966-2 · Cited by 1,643
The NF-κB signaling system in the immunopathogenesis of inflammatory bowel disease
Mukherjee, T., Kumar, N., Chawla, M., Philpott, D. J., & Basak, S. (2024) · Science Signaling · doi:10.1126/scisignal.adh1641 · Cited by 193
Thomas, T. R., Friedrich, M., Rich‐Griffin, C., Pohin, M., Agarwal, D., Pakpoor, J., Lee, C., Tandon, R., Rendek, A., Aschenbrenner, D., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01994-8 · Cited by 156
Immune-mediated inflammatory diseases: common and different pathogenic and clinical features
Monteleone, G., Moscardelli, A., Colella, A., Marafini, I., & Salvatori, S. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103410 · Cited by 105
The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease
Korta, A., Kula, J., & Gomułka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210172 · Cited by 93
Metadata
- Authors
- Parigi, T. L., Iacucci, M., & Ghosh, S.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University College Cork (IE)
- Corresponding author
- Ghosh, Subrata
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-04-01
- Volume
- 16
- Issue
- Supplement_2
- Pages
- ii64-ii72
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- PMC
- PMC9097679
- OpenAlex
- W4230705380
- Semantic Scholar
- 302cfe97be6c87bc02e3f610d0314c67ac00d4d0
- Cited by
- 93
- References
- 65
- Citations by year
- 2026: 9 · 2025: 27 · 2024: 25 · 2023: 26 · 2022: 6
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Crohn s and Colitis (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- AbbVie
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- IL-23
- MeSH terms
- Ustekinumab, Colitis, Ulcerative, Crohn Disease, Humans, Inflammatory Bowel Diseases, Interleukin-23
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blockade of IL-23: What is in the Pipeline? https://app.cochat.ai/papers/10.1093/ecco-jcc/jjab185
- The paper
- Parigi, T. L., Iacucci, M., & Ghosh, S. (2022). Blockade of IL-23: What is in the Pipeline? Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjab185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

